Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E in NPDR
NCT04782128Phase 2Active, not recruiting
- Sponsor
- RemeGen
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflimrufusp alfa, sponsored by RemeGen. Started May 2021; status: active, not recruiting.
02
Drugs
eflimrufusp alfa
Beyond the preview
Go deeper on NCT04782128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782128.